Home  /  Resource Library  /  Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL

Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL

ASH 2020: Results of a phase I/II study examining CAR T product AUTO3 in combination with pembrolizumab for treatment of relapsed diffuse large b-cell lymphoma.